|
| 36918461 | Covalently Binding Adenosine A<sub>3</sub> Receptor Agonist ICBM Irreversibly Reduces Voltage-Gated Ca<sup>2+</sup> Currents in Dorsal Root Ganglion Neurons. | Purinergic Signal | 2024 |
| 36711594 | Anionic Phospholipids Control Mechanisms of GPCR-G Protein Recognition. | bioRxiv | 2023 |
| 37562117 | Structure activity relationships of 5-HT<sub>2B</sub> and 5-HT<sub>2C</sub> serotonin receptor antagonists: N<sup>6</sup>, C2 and 5'-Modified (N)-methanocarba-adenosine derivatives. | Eur J Med Chem | 2023 |
| 37705595 | First Potent Macrocyclic A<sub>3</sub> Adenosine Receptor Agonists Reveal G-Protein and β-Arrestin2 Signaling Preferences. | ACS Pharmacol Transl Sci | 2023 |
| 37705594 | Assay-Dependent Inverse Agonism at the A<sub>3</sub> Adenosine Receptor: When Neutral Is Not Neutral. | ACS Pharmacol Transl Sci | 2023 |
| 37741687 | A<sub>2A</sub> adenosine receptor agonists, antagonists, inverse agonists and partial agonists. | Int Rev Neurobiol | 2023 |
| 37541364 | Anti-inflammatory potency of novel ecto-5'-nucleotidase/CD73 inhibitors in astrocyte culture model of neuroinflammation. | Eur J Pharmacol | 2023 |
| 37605951 | Cannabidiol negatively modulates adenosine A<sub>2A</sub> receptor functioning in living cells. | Acta Neuropsychiatr | 2023 |
| 37603740 | Specific inhibition of an anticancer target, polo-like kinase 1, by allosterically dismantling its mechanism of substrate recognition. | Proc Natl Acad Sci U S A | 2023 |
| 37603705 | Structure-Activity Relationship of Truncated 2,8-Disubstituted-Adenosine Derivatives as Dual A<sub>2A</sub>/A<sub>3</sub> Adenosine Receptor Antagonists and Their Cancer Immunotherapeutic Activity. | J Med Chem | 2023 |
| 37676356 | Editorial: Small molecules and biologics for future purinergic therapeutics. | Purinergic Signal | 2023 |
| 35687212 | Fluorescent A<sub>2A</sub> and A<sub>3</sub> adenosine receptor antagonists as flow cytometry probes. | Purinergic Signal | 2023 |
| 37382926 | Alicyclic Ring Size Variation of 4-Phenyl-2-naphthoic Acid Derivatives as P2Y<sub>14</sub> Receptor Antagonists. | J Med Chem | 2023 |
| 37404375 | A<sub>2B</sub> adenosine receptor activation and modulation by protein kinase C. | iScience | 2023 |
| 37034662 | Terpenes from <i>Cannabis sativa</i> Induce Antinociception in Mouse Chronic Neuropathic Pain via Activation of Spinal Cord Adenosine A<sub>2A</sub> Receptors. | bioRxiv | 2023 |
| 37261289 | Editorial: Purinergic pharmacology, Volume II. | Front Pharmacol | 2023 |
| 36926457 | Structural Optimization and Anticancer Activity of Polo-like Kinase 1 (Plk1) Polo-Box Domain (PBD) Inhibitors and Their Prodrugs. | ACS Pharmacol Transl Sci | 2023 |
| 36781870 | Anionic phospholipids control mechanisms of GPCR-G protein recognition. | Nat Commun | 2023 |
| 36781825 | In vivo phenotypic validation of adenosine receptor-dependent activity of non-adenosine drugs. | Purinergic Signal | 2023 |
| 36538251 | Species dependence of A<sub>3</sub> adenosine receptor pharmacology and function. | Purinergic Signal | 2023 |
| 32424811 | Adenosine A<sub>2A</sub> receptor antagonists: from caffeine to selective non-xanthines. | Br J Pharmacol | 2022 |
| 35408685 | Development of Bicyclo[3.1.0]hexane-Based A<sub>3</sub> Receptor Ligands: Closing the Gaps in the Structure-Affinity Relationships. | Molecules | 2022 |
| 35572558 | Optical Control of Adenosine A<sub>3</sub> Receptor Signaling: Towards a Multimodal Phototherapy in Psoriasis? | Front Immunol | 2022 |
| 35395239 | Kinetic profiling and functional characterization of 8-phenylxanthine derivatives as A<sub>2B</sub> adenosine receptor antagonists. | Biochem Pharmacol | 2022 |
| 35566035 | Pathophysiological Role and Medicinal Chemistry of A<sub>2A</sub> Adenosine Receptor Antagonists in Alzheimer's Disease. | Molecules | 2022 |
| 35454173 | Synthesis and Effect of Conformationally Locked Carbocyclic Guanine Nucleotides on Dynamin. | Biomolecules | 2022 |
| 35450351 | Selective A<sub>3</sub> Adenosine Receptor Antagonist Radioligand for Human and Rodent Species. | ACS Med Chem Lett | 2022 |
| 35814244 | Machine Learning for Discovery of New ADORA Modulators. | Front Pharmacol | 2022 |
| 36494860 | Novel alendronate-CGS21680 conjugate reduces bone resorption and induces new bone formation in post-menopausal osteoporosis and inflammatory osteolysis mouse models. | Arthritis Res Ther | 2022 |
| 36150180 | Structure-Activity Relationship and Neuroprotective Activity of 1,5-Dihydro-2<i>H</i>-naphtho[1,2-<i>b</i>][1,4]diazepine-2,4(3<i>H</i>)-diones as P2X4 Receptor Antagonists. | J Med Chem | 2022 |
| 36367749 | Structure-Activity Studies of 1<i>H</i>-Imidazo[4,5-<i>c</i>]quinolin-4-amine Derivatives as A<sub>3</sub> Adenosine Receptor Positive Allosteric Modulators. | J Med Chem | 2022 |
| 36362112 | Adenosine A<sub>3</sub> Receptor (A<sub>3</sub>AR) Agonist for the Treatment of Bleomycin-Induced Lung Fibrosis in Mice. | Int J Mol Sci | 2022 |
| 36268115 | Effects of Purinergic Receptor Deletion or Pharmacologic Modulation on Pulmonary Inflammation in Mice. | ACS Pharmacol Transl Sci | 2022 |
| 35983277 | Characterization of Dual-Acting A<sub>3</sub> Adenosine Receptor Positive Allosteric Modulators That Preferentially Enhance Adenosine-Induced Gα<sub>i3</sub> and Gα<sub>oA</sub> Isoprotein Activation. | ACS Pharmacol Transl Sci | 2022 |
| 36089113 | Synthesis and pharmacological characterization of multiply substituted 2H-chromene derivatives as P2Y<sub>6</sub> receptor antagonists. | Bioorg Med Chem Lett | 2022 |
| 35977382 | GPCR Agonist-to-Antagonist Conversion: Enabling the Design of Nucleoside Functional Switches for the A<sub>2A</sub> Adenosine Receptor. | J Med Chem | 2022 |
| 36003949 | Stereospecific antiseizure activity in mouse and rat epilepsy models by a pyridinium inhibitor of TNFα/NFκB signaling. | Eur J Med Chem Rep | 2022 |
| 35152062 | Interaction of A<sub>3</sub> adenosine receptor ligands with the human multidrug transporter ABCG2. | Eur J Med Chem | 2022 |
| 35093182 | Targeting the A<sub>3</sub> adenosine receptor to prevent and reverse chemotherapy-induced neurotoxicities in mice. | Acta Neuropathol Commun | 2022 |
| 35302044 | International Union of Basic and Clinical Pharmacology. CXII: Adenosine Receptors: A Further Update. | Pharmacol Rev | 2022 |
| 35113556 | Bridged Piperidine Analogues of a High Affinity Naphthalene-Based P2Y<sub>14</sub>R Antagonist. | J Med Chem | 2022 |
| 35231671 | Adipocyte purinergic receptors activated by uracil nucleotides as obesity and type 2 diabetes targets. | Curr Opin Pharmacol | 2022 |
| 35080883 | Structure-Activity Relationship of 3-Methylcytidine-5'-α,β-methylenediphosphates as CD73 Inhibitors. | J Med Chem | 2022 |
| 35335209 | Dihydropyridines Potentiate ATP-Induced Currents Mediated by the Full-Length Human P2X5 Receptor. | Molecules | 2022 |
| 34844790 | A<sub>3</sub> adenosine receptor agonists containing dopamine moieties for enhanced interspecies affinity. | Eur J Med Chem | 2022 |
| 34844537 | A<sub>2A</sub> Adenosine Receptor Antagonists in Neurodegenerative Diseases. | Curr Med Chem | 2022 |
| 34075613 | Spinal A<sub>3</sub> adenosine receptor activation acutely restores morphine antinociception in opioid tolerant male rats. | J Neurosci Res | 2022 |
| 32794053 | Tribute to Prof. Geoffrey Burnstock: transition of purinergicsignaling to drug discovery. | Purinergic Signal | 2021 |
| 35480676 | Convergent synthesis of 2-thioether-substituted (<i>N</i>)-methanocarba-adenosines as purine receptor agonists. | RSC Adv | 2021 |
| 33792561 | UDP-glucose and P2Y14 receptor amplify allergen-induced airway eosinophilia. | J Clin Invest | 2021 |